Enzymotec Ltd (NASDAQ:ENZY) has been upgraded to Hold in a statement by Zacks Investment Research earlier today.
- Updated: October 16, 2016
Having a price of $7.10, Enzymotec Ltd (NASDAQ:ENZY) traded -1.61% lower on the day. With the last close down -9.47% from the two hundred day average, compared with the S&P 500 Index which has decreased -0.01% over the same period. Enzymotec Ltd has recorded a 50-day average of $7.23 and a two hundred day average of $8.10. Trade Volume was down over the average, with 7,807 shares of ENZY changing hands under the typical 26,718
Zacks Investment Research has upgraded Enzymotec Ltd (NASDAQ:ENZY) to Hold in a statement released on Tuesday October 11, 2016.
On 08/13/2015, Canaccord Genuity released a statement on Enzymotec Ltd (NASDAQ:ENZY) upped the target price from $10.00 to $11.00 that suggested an upside of 0.14%.
With a total market value of $0, Enzymotec Ltd has price-earnings ratio of 38.58 with a one year low of $6.60 and a one year high of $10.32 .
More About Enzymotec Ltd (NASDAQ:ENZY)
Enzymotec Ltd. is a nutritional ingredients and medical foods company. The Company's technologies, research expertise and clinical validation process enables it to develop solutions across a range of products. The Company operates in two segments: Nutrition segment and VAYA Pharma segment. Both of the Company's segments offer a range of products that leverage its lipid-related offerings. Its product suite addresses the entire human life-cycle, from infancy to old age, and comprises ingredients in products ranging from infant formula to nutritional supplements, as well as branded medical foods, sold only under a doctor's supervision. It markets its product portfolio to established global consumer companies and physicians and target large and growing consumer health and wellness markets. The Company's clinically-validated products include bio-functional lipid-based compounds designed to address dietary needs, medical disorders and common diseases.
Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with MarketBeat.com's FREE daily email newsletter.